Tremelimumab(AstraZeneca)은 Muscle Invasive Bladder Cancer 표적 항체로, Hepatocellular Carcinoma 영역에서 개발·상용화 중입니다. 작용기전: targeting antigens like GPC3, AFP, and PD-L1, have been engineered to address antigen. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 24% (ClinicalTrials.gov NCT03095274). PK: t½ 16.9 h. 차별점: novel anticancer agents in non-small cell lung cancer: a pharmacovigilance analysis using the FAERS database.
Muscle Invasive Bladder Cancer
Hepatocellular Carcinoma
Recruiting
ADCs), have improved outcomes for patients with non-small cell
deruxtecan 3
humanized for CTLA-4 and Fcγ receptors (FcγR), we show that ipilimumab and tremelimumab exhibit l
novel anticancer agents in non-small cell lung cancer: a pharmacovigilance analysis using the FAERS database
targeting antigens like GPC3, AFP, and PD-L1, have been engineered to address antigen
immune-mediated myocarditis, autoimmune myocarditis, pericardial effusion, cardiac tamponade, malignant pericarditis, embolism, and thr
apoptosis, and metastasis
biomarkers for dual immune checkpoint blockade remain insufficiently defined
resistance to apoptosis, and metastasis
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Tremelimumab(AstraZeneca)은 Muscle Invasive Bladder Cancer 표적 항체로, Hepatocellular Carcinoma 영역에서 개발·상용화 중입니다. 작용기전: targeting antigens like GPC3, AFP, and PD-L1, have been engineered to address antigen. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 24% (ClinicalTrials.gov NCT03095274). PK: t½ 16.9 h. 차별점: novel anticancer agents in non-small cell lung cancer: a pharmacovigilance analysis using the FAERS database.
Muscle Invasive Bladder Cancer
Hepatocellular Carcinoma
Recruiting
ADCs), have improved outcomes for patients with non-small cell
deruxtecan 3
humanized for CTLA-4 and Fcγ receptors (FcγR), we show that ipilimumab and tremelimumab exhibit l
novel anticancer agents in non-small cell lung cancer: a pharmacovigilance analysis using the FAERS database
targeting antigens like GPC3, AFP, and PD-L1, have been engineered to address antigen
immune-mediated myocarditis, autoimmune myocarditis, pericardial effusion, cardiac tamponade, malignant pericarditis, embolism, and thr
apoptosis, and metastasis
biomarkers for dual immune checkpoint blockade remain insufficiently defined
resistance to apoptosis, and metastasis
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.